Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ranibizumab biosimilar - GENERIUM Pharmaceuticals

Next Previous
Drug Profile

Ranibizumab biosimilar - GENERIUM Pharmaceuticals

Alternative Names: GNR-067

Latest Information Update: 18 Aug 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GENERIUM Pharmaceuticals
  • Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Wet age-related macular degeneration

Most Recent Events

  • 03 Aug 2022 GENERIUM Pharmaceuticals completes a phase I trial in Macular degeneration (Parenteral) in Russia (GENERIUM Pharmaceuticals pipeline, August 2022)
  • 20 Mar 2022 Phase-III clinical trials in Wet age-related macular degeneration (Treatment-naive, In the elderly, In adults) in Russia (Intravitreous) (NCT04667039)
  • 11 Feb 2022 AO GENERIUM plans a phase III trial for Wet age-related macular degeneration (In adults, In the elderly, Treatment-naïve) in Russia (Intravitreous, Injection), in March 2022 (NCT04667039),

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top